ChemoCentryx Inc (NASDAQ:CCXI) Major Shareholder Sells $1,825,463.52 in Stock

ChemoCentryx Inc (NASDAQ:CCXI) major shareholder (International) Ltd Vifor sold 34,236 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $53.32, for a total value of $1,825,463.52. The sale was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

(International) Ltd Vifor also recently made the following trade(s):

  • On Wednesday, July 29th, (International) Ltd Vifor sold 88,012 shares of ChemoCentryx stock. The shares were sold at an average price of $52.58, for a total value of $4,627,670.96.
  • On Wednesday, July 22nd, (International) Ltd Vifor sold 72,469 shares of ChemoCentryx stock. The shares were sold at an average price of $55.58, for a total value of $4,027,827.02.
  • On Friday, July 24th, (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock. The shares were sold at an average price of $54.62, for a total value of $7,268,501.88.
  • On Monday, July 20th, (International) Ltd Vifor sold 54,598 shares of ChemoCentryx stock. The shares were sold at an average price of $56.03, for a total value of $3,059,125.94.
  • On Friday, July 17th, (International) Ltd Vifor sold 47,890 shares of ChemoCentryx stock. The shares were sold at an average price of $55.86, for a total value of $2,675,135.40.
  • On Wednesday, July 15th, (International) Ltd Vifor sold 86,298 shares of ChemoCentryx stock. The shares were sold at an average price of $59.22, for a total value of $5,110,567.56.
  • On Monday, July 13th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The shares were sold at an average price of $58.15, for a total value of $5,815,000.00.
  • On Friday, July 10th, (International) Ltd Vifor sold 45,844 shares of ChemoCentryx stock. The shares were sold at an average price of $59.92, for a total value of $2,746,972.48.
  • On Wednesday, July 8th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The shares were sold at an average price of $59.95, for a total value of $5,995,000.00.
  • On Monday, July 6th, (International) Ltd Vifor sold 86,690 shares of ChemoCentryx stock. The shares were sold at an average price of $58.44, for a total value of $5,066,163.60.

Shares of NASDAQ:CCXI opened at $52.71 on Friday. ChemoCentryx Inc has a 52-week low of $6.16 and a 52-week high of $65.43. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.22 and a current ratio of 3.22. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of -48.36 and a beta of 2.04. The stock’s 50-day simple moving average is $57.54 and its two-hundred day simple moving average is $50.31.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.05). ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. The company had revenue of $6.01 million for the quarter, compared to analysts’ expectations of $8.90 million. As a group, equities analysts forecast that ChemoCentryx Inc will post -1.39 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Sowell Financial Services LLC purchased a new position in shares of ChemoCentryx during the 1st quarter valued at about $28,000. GQ Asset Management LLC purchased a new position in shares of ChemoCentryx during the 1st quarter valued at about $46,000. Advisor Group Holdings Inc. purchased a new position in shares of ChemoCentryx during the 1st quarter valued at about $47,000. Exane Derivatives purchased a new position in shares of ChemoCentryx during the 1st quarter valued at about $86,000. Finally, Meeder Asset Management Inc. lifted its holdings in ChemoCentryx by 430.7% in the 1st quarter. Meeder Asset Management Inc. now owns 2,473 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 2,007 shares in the last quarter. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on CCXI shares. Raymond James raised their price target on ChemoCentryx from $38.00 to $102.00 and gave the company a “strong-buy” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price target on ChemoCentryx from $64.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday. Canaccord Genuity reiterated a “buy” rating on shares of ChemoCentryx in a report on Wednesday, June 3rd. Piper Sandler lifted their price objective on ChemoCentryx from $54.00 to $70.00 and gave the stock an “overweight” rating in a report on Monday, May 18th. Finally, BidaskClub downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. ChemoCentryx has a consensus rating of “Buy” and a consensus target price of $68.70.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

See Also: Cash Flow

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.